
Recent developments regarding the treatment and research of multiple myeloma indicate promising advances. [USA] A new bispecific antibody targeting BCMA is being tested in patients with relapsed multiple myeloma, while [UK] the inhibition of the NFIL3-MYC axis is emerging as a strategy to overcome therapeutic resistance. [Unidentified Country] New therapies, including CAR-T therapies and antibody combinations, are being approved, and FDA data analysis suggests the potential of Teclistamab with Daratumumab.
Made by MielomaAI On November 17, 2026, at 09:45, based on recent news. May contain errors. View news →
The plasmacytoma is the “physical” form of myeloma: instead of being scattered throughout the bone marrow, the diseased plasma cells clump together into a mass. It can be First stage of the diseaseAlone (solitary plasmacytoma, which is rare), or arising as a “child” of an existing myeloma.
What is a plasmacytoma?
It's a tumor made of plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. patients, all together in one place. It’s the “physical” form of myeloma: a mass that is seen on imaging tests and that, sometimes, can be felt by touch.
Multiple myeloma: plasma cell disorder
In multiple myeloma, the plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. patients are spreading bone marrowThe soft tissue inside the bones where blood cells are made: red blood cells, white blood cells, platelets, and plasma cells. It is examined with a bone marrow tap (bone marrow scan) or biopsy. It affects many bones. In the plasma cell tumorA tumor formed by plasma cells in one location. It can be in a bone (osseous) or in soft tissue, such as the nose or throat (extramedullary).They come together as one.
Spread out or in one placeSolitary bone plasmacytoma
It originates within a bone, primarily in the vertebrae, pelvis, femur, or ribs. It can cause pain, fracture the bone, or compress the nerves of the spine.
The most common of the lonely onesExtramedullary plasmacytoma
It originates outside the bones, in soft tissue: often in the nose, sinuses or throat, and more rarely in the stomach, intestines or lungs. It can cause a blocked nose, nosebleeds or hoarseness.
Out of the boneSometimes it is the first form of the disease.
In some patients, the plasma cell tumorA tumor formed by plasma cells in one location. It can be in a bone (osseous) or in soft tissue, such as the nose or throat (extramedullary). It's the first sign: it appears alone, before myeloma is present in the rest of the bone marrow. It's rare: in a large hospital, about 6 in every 100 patients with the disease plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. They had a solitary plasmacytoma.
First stage, in a few casesHow is it confirmed
A biopsy of the mass is performed to see if they are plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. from a single clone. Then myeloma is looked for in the rest of the body: bone marrow biopsyBone marrow examination, almost always in the pelvis, with local anaesthesia: a small amount of bone marrow is aspirated (bone marrow aspiration/myleogram) and a small piece of bone is taken (bone biopsy)., analyses of protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. and a whole-body imaging scanPETPositron emission tomography (PET) scan that shows the areas of the body with very active cells. Helps to see lesions in the bones and disease outside the bone marrow.- CT or MRI.
Full-body examsLonely, or with a little marrow
If there isn't plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. patients in the bone marrow, it's lonely. If there are a few, but less than 10%, it's called solitary with minimal bone marrow involvementWhen, in a solitary plasmacytoma, a few sick plasmocytes are found in the bone marrow, but less than 10%, the risk of progressing to myeloma is higher.And the risk of progressing to myeloma is quite a lot higher.
Change the riskThe treatment: radiotherapy
O plasma cell tumorA tumor formed by plasma cells in one location. It can be in a bone (osseous) or in soft tissue, such as the nose or throat (extramedullary). Solitary myeloma is generally treated with radiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. In the tumor area, every weekday for approximately 4 weeks. It often disappears. In the extramedularOutside the bone marrow: plasmacytoma tumors in organs or soft tissues (skin, liver, lymph nodes, nervous system). This indicates a more aggressive disease. You can also undergo surgery.
Around 4 weeksThe "children" of myeloma
In a patient who already has myeloma, new plasmacytomas can develop: attached to one bone, growing outside of it.bone marrowPlasma tumors that arise in a bone and grow outside of it into surrounding tissues carry a lower risk than free-floating tumors in organs.), or loose in other organsextramedullary diseaseMultiple myeloma with extramedullary deposits in organs or soft tissues, away from the bones (skin, liver, lymph nodes, nervous system). This indicates a more aggressive disease.They are like "sons" that the myeloma launches from the bone marrow.
In diagnosis or relapseWhen it's a sign of a more aggressive illness
Loose plasmacytomas, away from the bones—on the skin, liver, lymph nodes, or nervous system—indicate a more aggressive myeloma. They are treated with the general myeloma treatment, often more intense, and sometimes with radiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain..
High riskWatch closely for years.
Approximately half of solitary bone plasmacytomas and around three in ten extramedullary plasmacytomas progress to myeloma within 10 years. Therefore, regular monitoring and imaging tests are carried out, even if the tumor has disappeared.
Regular follow-upSigns to immediately alert the team
A new pain in a bone, a lump that grows, weakness or tingling in the legs, or loss of control of urine or feces: contact your team or go to the emergency room immediately. There is hope, there is a way forward.
Don't wait for the appointment.Simplified explanation for patients and families. Only the hematology team can say what type of multiple myeloma it is and what the best treatment is. Source: Caers et al., Journal of Hematology & Oncology 2018 — recomendações europeias para o plasmocitoma solitário ↗ · This does not replace the explanation from your medical team.
Types of Multiple Myeloma
It arises from the myeloma. plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody., as células da bone marrowThe soft tissue inside the bones where blood cells are made: red blood cells, white blood cells, platelets, and plasma cells. It is examined with a bone marrow tap (bone marrow scan) or biopsy. What antibodies do. Not all multiple myeloma are the same: they change phase, the protein they produce and the risk.
Before myeloma: MGUS
There is plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. modified and a little abnormal protein in the blood (a) protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working.), but without symptoms or damage. It's not cancer and it's not treated: it's monitored with tests.
Progresses slowly: about 1% per yearSmouldering myeloma
More protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working.Or 10% or more plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. in the bone marrow, but without damage to the organs. Most cases are monitored; in latentSmoldering myeloma: protein M of 3 g/dL or higher, or 10% to 60% plasma cells in the bone marrow, but without organ damage. Approximately 10% per year evolve to active myeloma in the first 5 years. High risk may already be treatable.
Close monitoringActive myeloma
When myeloma has already caused damage – high calcium, kidneys affected, AnemiaLack of red blood cells or hemoglobin in the blood. Causes fatigue, paleness, and shortness of breath. or bone injuries (the signsCRABThe English acronym for the 4 typical damages of myeloma: C for high calcium in the blood, R for kidneys (kidney failure), A for anemia, and B for bone, i.e., lesions in the bones. Just one of these is enough to speak of active myeloma.) — or when tests show it’s going to cause it soon. Then treatment is needed.
It needs to be treated.The protein type
Each antibody has 2 heavy chainsThe larger parts of an antibody. There are 5 types – G, A, D, E and M – and they are what give the immunoglobulin its name: IgG, IgA, IgD, IgE or IgM. e 2 fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone.. Multiple myeloma is named after the heavy chain (G, A, D, E or M) and the light chainkappaOne of the two light chain types. Approximately 2 in every 3 multiple myeloma cases are kappa. or That's a good question.One of the two light chain types. Approximately 1 in every 3 multiple myeloma cases is lambda; it is also the most common type in AL amyloidosis.:) for example, “IgG kappa”.
Discovered with immunofixationIgG and IgA
IgG is the most common: more than half of patients. IgA follows, and more often forms tumors outside of the bones. The treatment is generally the same.
The most commonLight Chain Myeloma
Approximately 1 in every 5 patients only produces fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. It (the protein) Bence JonesOld term for light chains found in urine. It comes from the English doctor who described them in the 19th century.). They are small and can block the kidneys, which need extra attention. Followed by with... free catenaryLoose pieces of antibody floating in the blood. The two types (kappa and lambda) are measured, as well as the ratio between them; a very high alteration indicates a clone of plasma cells. in the blood.
Around 20% of patientsRare conditions
IgD, IgE and IgM are rare. In smoldering myeloma (1-2% of patients), there is almost no protein detected in the blood tests: follow-up with bone marrow examination and imaging tests, such as PETPositron emission tomography (PET) scan that shows the areas of the body with very active cells. Helps to see lesions in the bones and disease outside the bone marrow..
RareSolitary plasmacytoma
A single tumor plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody.It can be in a bone, or outside of one, without myeloma in the rest of the bone marrow. It is often treated with radiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. and then you are monitored, as it can progress.
Radiotherapy and monitoringThe most dangerous: genetics
Some changes in the chromosomes of myeloma cells make the disease more aggressive: loss of 17pA fragment of chromosome 17 where the TP53 gene is located, which controls cell growth. If it is lost (17p deletion), the myeloma tends to be more aggressive. or mutation TP53Gene that acts as a brake on cells. When it is altered (mutated or lost), the myeloma responds worse to some treatments., e t(4;14)Translocation: exchange of pieces between chromosomes 4 and 14. It doesn't count as high risk on its own; it does count when it's associated with gains in 1q or losses in 1p.t(14;16) or t(14;20) when joining to gain 1qLong arm of chromosome 1. Having extra copies (a gain of 1q) is common and makes the disease more difficult to control, especially when combined with other changes. or a loss of 1 point. Two or more: even greater risk.
High riskThe most dangerous: outside the bone marrow
A Multiple myelomaRare and very aggressive condition: there are 5% or more plasma cells circulating in the blood. It can occur at the onset (primary) or as a relapse of myeloma (secondary). (5% or more) plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. (circulating in the blood) and the extramedullary diseaseMultiple myeloma with extramedullary deposits in organs or soft tissues, away from the bones (skin, liver, lymph nodes, nervous system). This indicates a more aggressive disease. Extramedullary disease is the most aggressive form.
Very high riskThe most common treatment at the beginning
Today, a combination of 4 medications is often used: one anti-CD38Antibodies (daratumumab, isatuximab) that bind to the CD38 protein, which is very prevalent in myeloma cells, and mark them for destruction by the immune system. (daratumumab), a proteasome inhibitorMedications (bortezomib, carfilzomib, ixazomib) that block the protein “breaker” in the cell. The myeloma cells, which produce a lot of protein, accumulate waste and die. (bortezomib), a immunomodulatorTablets (lenalidomide, pomalidomide, talidomide) that inhibit myeloma and help the body’s defenses attack it. lenalidomide and a corticosteroidCorticosteroid medications, such as dexamethasone. At high doses, they kill myeloma cells and enhance the effect of other medications. (dexamethasone)
Introduction: several monthsAfter the induction
Who can, does. allogeneic transplantStem cells are collected from the patient's own body, followed by intensive chemotherapy (melfalan) and then the cells are returned to the bone marrow to recover.And it involves using your own stem cells. Following this... MaintenanceMilder and longer treatment after induction and transplant, to keep the myeloma under control for a longer period. Often it is lenalidomide in tablet form.Generally, with lenalidomide, to keep the disease under control.
Transplant and maintenanceIf the disease returns
There are other weapons: new combinations, antibodies. Specific biomarkersAntibodies with two “arms”: one grabs the T lymphocyte and the other the myeloma cell, joining them so that the lymphocyte destroys. Examples: teclistamab, elranatamab, talquetamab. e CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion.In high-risk myeloma, doctors often treat more intensively and may propose clinical trialsStudies comparing a new treatment with the best existing treatment may provide access to medications before approval. Participation is voluntary..
RelapseTaking care of the rest of your body
In all types: medications to strengthen bones, vaccines and prevention of infections, and attention to the kidneys are part of the treatment.
AlwaysAll types, one by one
Under the film is the complete list: each type, what it is, how it progresses or is treated, and the risk, including related diseases, such as Amyloidosis ALDisease in which the light chains misfold and deposit themselves in the organs (heart, kidneys, nerves), damaging them. It can exist on its own or with multiple myeloma. e a POEMSRare syndrome linked to a plasma cell clone (almost always lambda): Polyneuropathy, Organomegaly, Endocrinopathy, M Protein and Skin Changes..
Movie listings belowAsk what your symptoms are.
Each myeloma is different. Ask your team: what is my type, what stage am I in, and what is my risk? There is hope, there is a path.
Simplified explanation for patients and families. The type, stage and risk for each person can only be determined by the hematology team. Source: International Myeloma Foundation — Types of Myeloma ↗ · This does not replace the explanation from your medical team.
Click on a type to open. Hover over (or tap) the underlined words to see what they mean.
Before myeloma
MGUS is not IgM.
- What is it?
- Protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. Low levels of IgG or IgA, less than 10%. plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. in the bone, without damage to the body. It is the most common form MGUSMonoclonal gamopathy of undetermined significance. There is protein M (less than 3 g/dL) and less than 10% plasma cells in the bone marrow, without organ damage. It affects approximately 3 in 100 people over 50 years old, and most will never develop myeloma..
- How to follow up or manage
- This isn't a cure. Tests are usually done 6 months after diagnosis and then once a year, or as needed based on risk.
- Risk
- Low: approximately 1% per year progresses to myeloma.
MGUS IgM
- What is it?
- Protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. Of the IgM type, without causing any damage to the body.
- How to follow up or manage
- Monitoring with analyses.
- Risk
- It can mainly progress to multiple myeloma. WaldenströmWaldenström macroglobulinemia: a lymphoma that produces IgM protein. It is not multiple myeloma and is treated differently. or another lymphoma, rarely for myeloma.
Light Chain MGUS
- What is it?
- Just fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. changes in the blood, without protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. complete and without harm.
- How to follow up or manage
- Monitoring with tests, including kidney assessments.
- Risk
- Low; can progress to myeloma fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. or Amyloidosis ALDisease in which the light chains misfold and deposit themselves in the organs (heart, kidneys, nerves), damaging them. It can exist on its own or with multiple myeloma..
Smouldering myeloma
- What is it?
- Protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. 3 g/dL or more, or 10% to 60% plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. in the bone marrow, but without signs CRABThe English acronym for the 4 typical damages of myeloma: C for high calcium in the blood, R for kidneys (kidney failure), A for anemia, and B for bone, i.e., lesions in the bones. Just one of these is enough to speak of active myeloma..
- How to follow up or manage
- Close monitoring (every 3 or 6 months), with imaging tests. No latentSmoldering myeloma: protein M of 3 g/dL or higher, or 10% to 60% plasma cells in the bone marrow, but without organ damage. Approximately 10% per year evolve to active myeloma in the first 5 years. high risk may involve daratumumab or entering a clinical trial.
- Risk
- Approximately 10% per year for the first 5 years. High risk when there are 2 or 3 of these: more than 20% plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody., protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. above 2 g/dL, reason for fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. Over 20.
Active myeloma
Multiple myeloma active
- What is it?
- Plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. multiple myeloma in the bone marrow with damage CRABThe English acronym for the 4 typical damages of myeloma: C for high calcium in the blood, R for kidneys (kidney failure), A for anemia, and B for bone, i.e., lesions in the bones. Just one of these is enough to speak of active myeloma. (calcium, kidneys, ) AnemiaLack of red blood cells or hemoglobin in the blood. Causes fatigue, paleness, and shortness of breath.... (bones) or with signs that they are about to cause them: 60% or more plasma cells, reason of fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. Of 100 or more, or more than one bone lesion seen on the scan.
- How to follow up or manage
- Treatment of inductionThe first phase of treatment aims to reduce the myeloma levels as much as possible. It usually lasts for several months. (often 4 medications) allogeneic transplantStem cells are collected from the patient's own body, followed by intensive chemotherapy (melfalan) and then the cells are returned to the bone marrow to recover. in whom it may concern MaintenanceMilder and longer treatment after induction and transplant, to keep the myeloma under control for a longer period. Often it is lenalidomide in tablet form..
- Risk
- It depends on the stage (R-ISS) and genetics.
Types by protein (immunofixation)
IgG (kappa or lambda)
- What is it?
- The most common type: more than half of patients.
- How to follow up or manage
- Typical treatment for myeloma. Followed by… protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. in the blood.
- Risk
- Just like overall; the risk depends mainly on genetics and stage.
IgA (kappa or lambda)
- What is it?
- The second most common, about 1 in every 5 patients.
- How to follow up or manage
- Standard treatment. Sometimes it protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. It is measured worse and IgA dosage is also used.
- Risk
- More frequently, tumors outside of the bones.
Light chains (Bence Jones), kappa or lambda
- What is it?
- Just produces fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone., without the heavy chain. Around 15% to 20% of patients.
- How to follow up or manage
- Standard treatment, with particular attention to the kidneys (hydration, avoiding anti-inflammatory drugs). Followed by… free catenaryLoose pieces of antibody floating in the blood. The two types (kappa and lambda) are measured, as well as the ratio between them; a very high alteration indicates a clone of plasma cells. in the blood.
- Risk
- Increased risk of kidney injury.
IgD
- What is it?
- Rare: about 1 to 2% of patients. Almost always That's a good question.One of the two light chain types. Approximately 1 in every 3 multiple myeloma cases is lambda; it is also the most common type in AL amyloidosis. and in younger people too.
- How to follow up or manage
- Standard treatment; often proposes transplant.
- Risk
- Further kidney damage and disease outside the bone marrow; may be associated with Multiple myelomaRare and very aggressive condition: there are 5% or more plasma cells circulating in the blood. It can occur at the onset (primary) or as a relapse of myeloma (secondary)..
IgE
- What is it?
- Very rare: less than 1 in 1000 patients.
- How to follow up or manage
- Typical treatment.
- Risk
- It tends to be more aggressive and spread to the bloodstream.
IgM
- What is it?
- Very rare. It is necessary to distinguish from macroglobulinemia. WaldenströmWaldenström macroglobulinemia: a lymphoma that produces IgM protein. It is not multiple myeloma and is treated differently.Also produces IgM but is a lymphoma.
- How to follow up or manage
- Treatment of myeloma, after diagnosis has been confirmed.
- Risk
- More difficult to diagnose; tends to be more aggressive.
Biclonal
- What is it?
- Rare (1-2%) : there are two different M proteins present at the same time.
- How to follow up or manage
- Typical treatment; followed by the two proteins.
- Risk
- Similar to general.
Non-secretor and oligoscretor
- What is it?
- Non-secretor: almost no protein in the tests (1 to 2% of patients). Oligosecretor: very little protein.
- How to follow up or manage
- Standard treatment; followed by bone marrow and imaging tests.PETPositron emission tomography (PET) scan that shows the areas of the body with very active cells. Helps to see lesions in the bones and disease outside the bone marrow.MRI scan).
- Risk
- Similar to the general case, but it’s harder to see if the treatment is working.
Localized and aggressive forms
Solitary bone plasmacytoma
- What is it?
- A single tumor plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. in one bone, without myeloma in the rest of the marrow.
- How to follow up or manage
- RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. in the tumor area; then monitoring.
- Risk
- Approximately half progress to myeloma within 10 years.
Solitary extramedullary plasmacytoma
- What is it?
- A single tumor outside the bones, often in the nose, sinuses, or throat.
- How to follow up or manage
- RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. or surgery; then observation.
- Risk
- Progresses less than bone myeloma.
Extramedullary Disease
- What is it?
- Multiple myeloma with tumors in organs or soft tissues (skin, liver, lymph nodes, nervous system), in diagnosis or, more often, in relapses.
- How to follow up or manage
- Intensive treatment CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. e Specific biomarkersAntibodies with two “arms”: one grabs the T lymphocyte and the other the myeloma cell, joining them so that the lymphocyte destroys. Examples: teclistamab, elranatamab, talquetamab. are options in relapse; clinical trialsStudies comparing a new treatment with the best existing treatment may provide access to medications before approval. Participation is voluntary..
- Risk
- High risk.
Multiple myeloma
- What is it?
- 5% or more plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. circulating in the blood. Primary (at the very beginning) or secondary (in a relapse).
- How to follow up or manage
- Intensive treatment and rapid response; transplant for those who can. clinical trialsStudies comparing a new treatment with the best existing treatment may provide access to medications before approval. Participation is voluntary..
- Risk
- Very high risk: the most aggressive form.
Related conditions (not myeloma)
AL Amyloidosis
- What is it?
- As fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. They fold badly and deposit themselves in the heart, kidneys, nerves, or liver.
- How to follow up or manage
- Treatment against the clone plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. (such as daratumumab with bortezomib, cyclophosphamide and dexamethasone) and care for the affected organs.
- Risk
- It mainly depends on the heart.
POEMS
- What is it?
- Rare syndrome with polyneuropathy, enlarged organs, hormonal changes. protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. It's almost always That's a good question.One of the two light chain types. Approximately 1 in every 3 multiple myeloma cases is lambda; it is also the most common type in AL amyloidosis.) and skin changes.
- How to follow up or manage
- RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. If the disease is localized to one area; otherwise, treatment as in myeloma and transplant.
- Risk
- Variable; nerves recover slowly.
MGRS (kidney-related)
- What is it?
- A small clone plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. That is not myeloma but damages the kidneys.
- How to follow up or manage
- Treatment targeting clones to protect the kidneys.
- Risk
- The risk is mainly for the kidneys.
Waldenström macroglobulinemia
- What is it?
- Lymphoma producing IgM. Not a myeloma.
- How to follow up or manage
- Self-treatment for lymphoma (e.g., BTK inhibitors or rituximab).
- Risk
- Generally progresses slowly.
And the risk for each person?
The risk doesn't just depend on the type. Doctors use the R-ISS or R2-ISS stage… beta-2 microglobulinProtein measured in the blood. High values indicate more disease and are included in the staging (ISS) calculation.The albumin, the LDHMeasured enzyme (lactate dehydrogenase). High values may indicate more active disease. and genetics) and are looking for high-risk changes: loss of 17pA fragment of chromosome 17 where the TP53 gene is located, which controls cell growth. If it is lost (17p deletion), the myeloma tends to be more aggressive. or mutation TP53Gene that acts as a brake on cells. When it is altered (mutated or lost), the myeloma responds worse to some treatments.It’s a condition where parts of your chromosomes swap places. t(4;14)Translocation: exchange of pieces between chromosomes 4 and 14. It doesn't count as high risk on its own; it does count when it's associated with gains in 1q or losses in 1p.t(14;16) or t(14;20) alongside gains 1qLong arm of chromosome 1. Having extra copies (a gain of 1q) is common and makes the disease more difficult to control, especially when combined with other changes. or a loss of 1 point, and very high beta-2 microglobulin with normal kidneys. Two or more changes = an even greater risk.
| Type | Where | How frequent | Treatment | Risk of myeloma |
|---|---|---|---|---|
| Solitary bone plasmacytoma | Inside a bone: vertebrae, pelvis, femur, ribs. | Approximately 4 in 100 patients with plasmacytosis disease. | RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. (40 to 50 Gy, approximately 4 weeks) | Approximately half progress to myeloma within 10 years. |
| Solitary extramedullary plasmacytoma | Outside the bone: nose, sinuses, throat; less commonly stomach, intestines, lungs. | About 2 in every 100. | RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain.Sometimes surgery. | About 3 in 10 progress to the advanced stages within 10 years. |
| Solitary with minimal involvement of the bone marrow | It plasma cell tumorA tumor formed by plasma cells in one location. It can be in a bone (osseous) or in soft tissue, such as the nose or throat (extramedullary). and less than 10% plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. Patients in the bone marrow. | Monitor closely when using sensitive techniques (flow cytometry). | RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. and closer monitoring; sometimes a clinical trial. | Much larger: in a study, 7 out of 10 progressed (compared to less than 1 in 10 without affected marrow). |
| Vertebral plasmacytomas (in multiple myeloma) | They are born in a bone and grow into the surrounding tissues. | Relatively common in the diagnosis of multiple myeloma. | General myeloma treatment radiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. If you're feeling anxious or in pain. | Falls under myeloma; intermediate risk. |
| Extramedullary disease (in myeloma) | Afflictions in organs distant from the bones: skin, liver, lymph nodes, nervous system. | Rare in the diagnosis; more common in relapses. | Intensive treatment CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. e Specific biomarkersAntibodies with two “arms”: one grabs the T lymphocyte and the other the myeloma cell, joining them so that the lymphocyte destroys. Examples: teclistamab, elranatamab, talquetamab. in relapse clinical trialsStudies comparing a new treatment with the best existing treatment may provide access to medications before approval. Participation is voluntary.. | High risk: more aggressive disease. |
Numbers of the European recommendations for solitary plasmacytomaCaers et al., 2018 ↗Gray (Gy) is the unit of radiation therapy dose. Each case is assessed by the hematology and radiation therapy team.

Comprehensive and up-to-date news coverage, gathered from sources around the world by Google News.

Ben Derman: Top 10 Myeloma Abstracts to Be Presented at ASH 2026 / ASCO, ASH 2026, Ben Derman, cancer, CAR-T, DARA, Daratumumab, Lenalidomide, Mount Sinai

MRD is becoming a very valuable tool, but it's not an exclusive tool, says expert
All news → · Summaries created by MielomaAI; expand the article to read the original.
